Jun 18, 2026Effective9999999995-26-002066
All companies
Trade Hcw Biologics Inc
Nasdaq grants HCW Biologics extension to regain minimum bid compliance
Hcw Biologics Inc
HCWBPublicArchived
Public / ArchivedUnited States(Nasdaq)Best valuation $8.31M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Not available
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-edgar, sec-harvest, nasdaq
IPO Calendar · NasdaqIPO
HCWBPrice
$1.16
24h
+6.42%
Valuation
$8.31M
24h volume
$5.21M
Type
IPO
Trade Hcw Biologics IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 1h ago
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001828673.
Revenue
—
Net income
-$7.96M
Gross margin
—
Cash
$1.95M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross profit | $10.85K | $959.4K | $560.36K | $2.59M | $0 |
| Operating income | -$13.16M | -$29.46M | -$25.72M | -$15.08M | -$13.37M |
| Net income | -$7.96M | -$30.02M | -$24.99M | -$14.9M | -$12.86M |
| R&D expense | $5.44M | $6.39M | $7.68M | $9.34M | $8.17M |
| Cash & equivalents | $1.95M | $4.67M | $3.6M | $22.33M | $11.73M |
| Total assets | $24.52M | $30.24M | $28.51M | $46.81M | $53.51M |
| Total liabilities | $21.76M | $37.01M | $15.05M | $9.38M | $2.32M |
| Shareholders' equity | $2.76M | -$6.77M | $13.46M | $37.43M | $51.19M |
About Hcw Biologics Inc
Hcw Biologics Inc is speculative and involves a high degree of risk.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Hcw Biologics Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
EffectiveEDGAR filings resolved from HCWB / CIK 0001828673.
S-1/AS-1/A
Jun 18, 2026Amended0001493152-26-029235
S-1S-1
Jun 8, 2026Filed0001493152-26-027656
Apr 29, 2026Effective9999999995-26-001391
S-1/AS-1/A
Apr 24, 2026Amended0001493152-26-018992
S-1S-1
Apr 23, 2026Filed0001493152-26-018758
Apr 13, 2026Confidential draft0001493152-26-016232
424B4424B4
Feb 19, 2026Final prospectus0001193125-26-059279
Feb 17, 2026Effective9999999995-26-000619
S-1/AS-1/A
Feb 17, 2026Amended0001193125-26-053303
S-1/AS-1/A
Feb 13, 2026Amended0001193125-26-051317
CORRESPfilename1.htm
Feb 11, 2026SEC correspondence0001193125-26-047334
Latest Hcw Biologics Inc IPO news
Recent sourced articles classified for IPO relevance, with platform-access noise filtered out where possible.
Investing.comJun 1, 2026Market news
Investing.com reports that HCW Biologics received an extension from the Nasdaq Hearings Panel to regain compliance with the minimum bid price requirement, conditioned on achieving at least a $1 closing bid for 20 consecutive trading days by July 29, 2026.
Hcw Biologics Inc IPO — frequently asked questions
- When did Hcw Biologics Inc go public?
- Hcw Biologics Inc has already gone public and now trades publicly on Nasdaq under the ticker HCWB.
- Can I buy Hcw Biologics Inc stock?
- Yes — Hcw Biologics Inc is publicly traded on Nasdaq as HCWB. You can follow its live price, valuation and post-IPO performance above.
- What is Hcw Biologics Inc's valuation?
- Hcw Biologics Inc's most recent valuation tracked here is $8.31M, derived from live market prices.